stock-detail (LXRX)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/14/2017 06:17 am

4/14/2017 06:17 am

4/14/2017 06:17 am

4/14/2017 06:17 am

Lexicon To Present At The 16th Annual Needham Healthcare Conference

4/3/2017 11:00 am

[PR Newswire] - THE WOODLANDS, Texas, April 3, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 8:40 a.m. Eastern Time in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercializing XERMELO™ (telotristat ethyl), the first drug from its discovery platform to receive FDA approval, for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in neuropathic pain, diabetes and metabolism.

Lexicon To Present At The Barclays Global Healthcare Conference

3/9/2017 01:00 pm

[PR Newswire] - THE WOODLANDS, Texas, March 9, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m. Eastern Time in Miami. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercializing XERMELO™ (telotristat ethyl), the first drug from its discovery platform to receive FDA approval, for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in neuropathic pain, diabetes and metabolism.

Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference

3/6/2017 10:03 pm

[PR Newswire] - THE WOODLANDS, Texas, March 6, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, March 8, 2017 at 8:00 a.m. Eastern Time in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercializing XERMELO™ (telotristat ethyl), the first drug from its discovery platform to receive FDA approval, for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in neuropathic pain, diabetes and metabolism. For additional information please visit www.lexpharma.com.